Allworth Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Allworth Financial’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.95K	Sell	159 -80	-33%	-$2.97K	﹤0.01%	4025
2026 Q1	$8.68K	Sell	239 -13	-5%	-$581	﹤0.01%	3610
2025 Q4	$11.7K	Buy	252 +32	+15%	+$1.43K	﹤0.01%	3155
2025 Q3	$9.16K	Buy	220 +85	+63%	+$2.72K	﹤0.01%	3198
2025 Q2	$3.88K	Buy	135 +130	+2,600%	+$4.01K	﹤0.01%	3401
2025 Q1	$167	Sell	5 -4	-44%	-$149	﹤0.01%	3903
2024 Q4	$348	Sell	9 -15	-63%	-$839	﹤0.01%	3684
2024 Q3	$1.23K	Sell	24 -6	-20%	-$309	﹤0.01%	3150
2024 Q2	$1.58K	Buy	30 +10	+50%	+$462	﹤0.01%	3021
2024 Q1	$937	Hold	20	–	–	﹤0.01%	3102
2023 Q4	$712	Sell	20 -28	-58%	-$859	﹤0.01%	3053
2023 Q3	$1.43K	Buy	+48	New	+$989	﹤0.01%	2696
2023 Q2	–	Sell	-100	Closed	-$1.61K	–	3280
2023 Q1	$1.61K	Buy	+100	New	+$1.85K	﹤0.01%	2502
2022 Q4	–	Sell	-10	Closed	–	–	3046
2022 Q3	$0	Buy	+10	New	+$204	﹤0.01%	2731

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allworth Financial's CRNX Position: Q2 2026 in Review

Allworth Financial reduced its Crinetics Pharmaceuticals (CRNX) stake by 33% in Q2 2026, selling an estimated $2.97K and leaving 159 shares worth $5.95K. The position accounts for ﹤0.01% of the portfolio, ranked #4025.

Allworth Financial first reported a position in CRNX in Q3 2022 and has held it in 14 quarters since. The position peaked at $11.7K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Allworth Financial held 159 shares of Crinetics Pharmaceuticals worth $5.95K as of Q2 2026.
Allworth Financial sold 80 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.97K.
Crinetics Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4025 holding.
Allworth Financial first reported a position in Crinetics Pharmaceuticals in Q3 2022 and has held it in 14 quarters since.
Allworth Financial's Crinetics Pharmaceuticals position peaked at $11.7K in Q4 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.